SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03973489

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Effects of Genotype on Resting State Connectivity During Methamphetamine Administration

Addiction to methamphetamine (MA) is a serious health problem in the United States. Right now, there are no medically approved treatments for MA dependence. More research is needed to understand how MA affects the brain and to eventually develop medical interventions for MA addiction. The purpose of the study is to learn more about how MA use affects the brain by investigating a receptor in the brain called trace amine-associated receptor 1 (TAAR1). The investigators are hoping to find out if individuals with certain versions of the brain receptor react differently when given MA. The TAAR1 receptor has two prevalent genetic variations due to a single nucleotide polymorphism. These are the wild type (WT) and a common variant (CV). Preliminary studies have shown that these variants produce different connectivity (resting state functional connectivity or RSFC) in the brains of individuals with MA use disorder (MUD), specifically that individuals with the CV genotype exhibit lower RSFC than WT. In this study, MA will be administered to individuals in order to: 1. Determine the influence of CV vs. WT genotype on RSFC and craving in individuals with chronic MUD. 2. Determine the effect of acute methamphetamine or placebo administration on the interaction of CV vs WT genotype on RSFC, craving, cognitive control, attention and subjective experience in MUD.

NCT03973489 Methamphetamine-dependence

3 Interventions

Name: Magnetic resonance imaging (MRI)

Description: On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.

Type: Behavioral

Common Variant (CV) Group Wild Type (WT) Group

Name: Methamphetamine Hydrochloride Tablets

Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.

Type: Drug

Common Variant (CV) Group Wild Type (WT) Group

Name: Placebo oral tablet

Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.

Type: Drug

Common Variant (CV) Group Wild Type (WT) Group


Primary Outcomes

Description: The magnitude of connectivity changes between groups during resting state will be assessed and reported using an analysis of variance (ANOVA).

Measure: Brain activation during resting state MRI

Time: 1 day

Time Perspective: Prospective

Case-Control


There is one SNP

SNPs


1 rs8192620

The SNP (rs8192620 on human [GRCh38.p7]



HPO Nodes